The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2022 | Association between the V122I TTR variant with heart failure in ATTR amyloidosis, SCD & leukemia
Kwaku Appiah-Kubi, PhD, Tedam University of Technology and Applied Science, Navrongo, Ghana, comments on the association between hereditary transthyretin (ATTRv) amyloidosis, sickle cell disease (SCD), leukemia, and heart failure. Dr Appiah-Kubi explains that studies have shown that the V122I TTR variant present in both patients with ATTRv amyloidosis and SCD has been associated with both sensory neural hearing loss and heart failure. In addition, patients with ATTRv amyloidosis, SCD, and leukemia have been shown to have an increased risk of heart failure, thereby highlighting the need to monitor patients with leukemia for the presence of the V122I variant. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
